Dear Reader, You’re about to witness a quantum leap in medicine. It’s been referred to as a ‘historic breakthrough’. And in the next 60 seconds, I’ll hand you an opportunity to see an up-close example of this breakthrough with your own two eyes…and decide for yourself. All the analysis I’ve scrutinised tells me a landmark development by one tiny Californian lab could help to completely reshape medical science as we know it. You see, they’ve developed a breakthrough ovarian cancer treatment experts call a: ‘living drug’. Preclinical tests have already proven this radical, new ‘drug’ shrinks aggressive ovarian cancer tumours. Now, this genius biotech is gearing up for human clinical trials. That’s exactly why you need to push aside 15 minutes of your time…and run your eyes over this letter — in full — NOW. If I’m right, and the FDA gives this firm the greenlight for human trials…I believe you could see the share price spike 2,422%. All my research tells me this company could receive the ‘thumbs up’ before 30 November. That doesn’t give you much time. So, let me fill you in on what makes this $59 million firm insanely special. Ovarian cancer is one of the most aggressive solid tumour cancers. Survival rates for stage 4 ovarian cancer stand at just 19%. Meaning, eight out of 10 women with late-stage ovarian cancer will succumb to the disease. In total, it kills 140,000 women worldwide every year. Another 225,000 will hear their doctors tell them they have this deadly disease for the very first time. Good news is, the company I’ll reveal today aims to wipe away ALL ovarian cancer deaths in one powerful blow. And this could be possible thanks to the remarkable living drug. I know it’s a huge claim… One ‘drug’ that defeats ovarian cancer. But this isn’t speculation or hype. The living drug has medical professionals whispering the one ‘C’ word they’re not supposed to say. Like oncologist and ovarian cancer specialist Dr Rebecca Kristeleit said in 2016: ‘We are starting to think about using that word: “cure”’...As an oncologist, it's not a word you would ever say...’ Dr Pardoll is Director of the cancer immunotherapy department at Johns Hopkins. His research focuses on tumour-based cancers, like ovarian cancer. He believes the living drug breakthrough has the potential to control — even cure — the most advanced-stage forms of cancer today. The cancer strains that resist all other treatments. ‘The potential to control or cure even the most advanced, treatment-resistant cancers has been elusive until now’. Dr Aya Jakobovits is a board member of the Alliance for Cancer Gene Therapy. She also holds a patent for a cancer therapy targeting aggressive cancers like ovarian cancer. She has gone one step further and declared… ‘It's the Holy Grail we're looking for’. These are not medical professionals that deal in ‘maybes’ or false promises. The ‘living drug’ is REAL… And it could be about to deliver a knock-out punch to ovarian cancer. This firm is in collaboration with leading cancer institutions like The Wistar Institute, Moffitt Cancer Centre, Delaware Valley Urology and the University of Pennsylvania. The CEO is a venture capitalist, earned a PhD from Caltech University and has trained at illustrious medical institutions like Harvard and Stanford. His previous business — an advanced clinical diagnostic company — netted investors a 127% gain in the 12 months leading up to a buy-out in November 2017. I believe his next project — the living drug — could send shares in this Californian company sky-high — in the magnitude of 25-fold. The FDA has approved living drug strains for ‘last resort’ cancer patients — people with late stage cancer who’ve tried everything and failed to beat the disease. But in the not-too-distant future, the living drug could be available to anyone diagnosed with this deadly affliction. Personally, I think this living drug could go down as the greatest medical discovery in history. Act early enough, and it could also rank as the greatest ground-floor investment opportunity you’ll see in your life. The way I see it, this could be bigger than the discovery of penicillin… And a GREATER scientific accomplishment than the completion of the human genome. Those two extraordinary medical feats alone bled into long-term, colossal stock gains like 4,094% and 23,388% for Pfizer and Celgene. Enough to make you a millionaire off a relatively small $3,000 investment. If I’ve pegged it right, and this US outfits’ ovarian living drug goes commercial in the months ahead, the opportunity in front of you today could eventually match…and possibly even exceed those long-range gains. And this potentially vertical share price trajectory begins with the extraordinary 10 second footage I’ll show you next. Brace yourself…. The short clip below will give you an up-close example of how this Californian biotech minnow has turned a miracle into reality… And you’re about to see an example of it with your own two eyes right now. |